RetinalGenix Technologies (RTGN) Liabilities and Shareholders Equity (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Liabilities and Shareholders Equity of $5805.0 for Q1 2026, down 51.35% on a YoY basis from $11931.0 in Q1 2025, and down 72.41% sequentially from $21041.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $5805.0 in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 51.35% year-over-year to $5805.0; the trailing twelve-month figure through Mar 2026 stood at $42235.0 (down 79.17% YoY), and the FY2025 full-year result was $21041.0, up 40.78% from the prior year.
- Liabilities and Shareholders Equity eased to $5805.0 in Q1 2026, from $21041.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $88854.0 in Q3 2024 to a low of $27.0 in Q2 2022.
- A 5-year average of $18381.9 and a median of $7001.0 in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity slumped 94.25% in 2023 and surged 39390.67% in 2024, its largest moves.
- Tracing RTGN's Liabilities and Shareholders Equity over 5 years: stood at $294.0 in 2022, then slumped by 46.94% to $156.0 in 2023, then soared by 9480.77% to $14946.0 in 2024, then jumped by 40.78% to $21041.0 in 2025, then tumbled by 72.41% to $5805.0 in 2026.
- Business Quant data shows RTGN's Liabilities and Shareholders Equity at $5805.0 in Q1 2026, $21041.0 in Q4 2025, and $7001.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 5,805.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,805.00 |
| Dec 31, 2025 | 21,041.00 |
| Sep 30, 2025 | 7,001.00 |
| Jun 30, 2025 | 8,388.00 |
| Mar 31, 2025 | 11,931.00 |
| Dec 31, 2024 | 14,946.00 |
| Sep 30, 2024 | 88,854.00 |
| Jun 30, 2024 | 87,019.00 |
| Mar 31, 2024 | 50,517.00 |
| Dec 31, 2023 | 156.00 |
| Sep 30, 2023 | 225.00 |
| Jun 30, 2023 | 2,119.00 |
| Mar 31, 2023 | 7,701.00 |
| Dec 31, 2022 | 294.00 |
| Sep 30, 2022 | 3,914.00 |
| Jun 30, 2022 | 27.00 |
| Mar 31, 2022 | 2,555.00 |
| Dec 31, 2021 | 4,947.00 |
| Sep 30, 2021 | 36,578.00 |
| Dec 31, 2020 | 61,075.00 |